Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.
Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.
The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.
There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.
The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.
This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.
With smart cameras playing a major role in the Nancy Guthrie case, Ring founder Jamie Siminoff addresses data security and privacy after that Super Bowl ad.
Rich Hill of Principal Asset Management breaks down where real estate capital is flowing, what’s driving returns, and how 2026 could reshape the market.
From surprise celebrity overload to fewer influencers, USA Today's Ralphie Aversa breaks down the biggest Super Bowl 60 ads and why AI quietly stole the show.
Carl Lukach, CFO of Bob’s Discount Furniture, shares insights on the company’s IPO, growth strategy, and what it means for the future of the furniture market.
